<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title>Sarepta Therapeutics Inc (SRPT): Sarepta Therapeutics: No Longer A Momentum Play, But Long-Term Value Remains - Seeking Alpha</title>
<meta http-equiv="Content-Type" content="text/html;charset=utf-8" />
<meta http-equiv="P3P" content='CP="IDC DSP COR ADM DEVi TAIi PSA PSD IVAi IVDi CONi HIS OUR IND CNT"' />

<script>
    (function(_,e,rr,s){_errs=[s];var c=_.onerror;_.onerror=function(){var a=arguments;_errs.push(a);
    c&&c.apply(this,a)};var b=function(){var c=e.createElement(rr),b=e.getElementsByTagName(rr)[0];
    c.src="//beacon.errorception.com/"+s+".js";c.async=!0;b.parentNode.insertBefore(c,b)};
    _.addEventListener?_.addEventListener("load",b,!1):_.attachEvent("onload",b)})
    (window,document,"script","4ffae9d6f05d1da630000008");
</script>

<script type='text/javascript'>
try {
  window.external.msSiteModeCreateJumplist('SeekingAlpha - Read, Decide, Invest.');
  window.external.msSiteModeAddJumpListItem('Portfolio' ,
  'http://seekingalpha.com/account/portfolio?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Market Currents - Real-time stock market news updates' ,
  'http://seekingalpha.com/currents/all?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Investment Ideas' ,
  'http://seekingalpha.com/dashboard/investing_ideas?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Income Investing, Retirement Investing and Dividend Stocks' ,
  'http://seekingalpha.com/dashboard/investing_income?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('ETFs & Portfolio Strategy' ,
  'http://seekingalpha.com/dashboard/etfs?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Macro View, Market Economy' ,
  'http://seekingalpha.com/dashboard/macro_view?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('My Email Alerts' ,
  'http://seekingalpha.com/account/email_preferences?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
} catch (ex) {
}
</script>
<meta name="application-name" content="Seeking Alpha - Read, Decide, Invest."/>
<meta name="msapplication-TileColor" content="#360000"/>
<meta name="msapplication-TileImage" content="http://static.cdn-seekingalpha.com/images/media_kit/71cdea92-2dc1-419d-8d62-f68b74c1eda8.png"/>
<meta name="msapplication-tooltip" content="Seeking Alpha - Read, Decide, Invest." />
<meta name="msapplication-starturl" content="http://seekingalpha.com?source=ie_task" />
<meta name="msapplication-task" content="name=Portfolio ;action-uri=http://seekingalpha.com/account/portfolio?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Market Currents - Real-time stock market news updates ;action-uri=http://seekingalpha.com/currents/all?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Investment Ideas ;action-uri=http://seekingalpha.com/dashboard/investing_ideas?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Income Investing, Retirement Investing and Dividend Stocks ;action-uri=http://seekingalpha.com/dashboard/investing_income?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=ETFs & Portfolio Strategy ;action-uri=http://seekingalpha.com/dashboard/etfs?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Macro View, Market Economy ;action-uri=http://seekingalpha.com/dashboard/macro_view?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=My Email Alerts ;action-uri=http://seekingalpha.com/account/email_preferences?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<!-- End IE9 Settings -->

<meta name="twitter:card" content="summary">
<meta name="twitter:site" content="@sa_popular">
<meta name="twitter:title" content="Sarepta Therapeutics: No Longer A Momentum Play, But Long-Term Value Remains">
<meta name="twitter:description" content="Sarepta Therapeutics (SRPT) demonstrated the binary nature of biotechnology investing Wednesday. The shorts were vindicated as the FDA told the company that it should not apply for approval based in Phase II data for eteplirsen, the company's drug for the treatment of Duchene's Muscular Dystrophy. However, unlike most companies that fail binary events where there is little value left, Sarepta shares still have the opportunity to recover.">
<meta name='twitter:image' content='http://static.cdn-seekingalpha.com/images/users_profile/001/003/340/big_pic.png?1320144828'><link rel="search" type="application/opensearchdescription+xml" href="/javascripts/seeking.xml" title="SeekingAlpha Search" />
<meta name="description" content="Sarepta Therapeutics Inc (NASDAQ:SRPT), GlaxoSmithKline plc (ADR) (NYSE:GSK), Prosensa Holding BV (NASDAQ:RNA): Sarepta Therapeutics: No Longer A Momentum Play, But Long-Term Value Remains" /><meta name="robots" content="noarchive" /><meta name="keywords" content="NASDAQ:SRPT, NYSE:GSK, NASDAQ:RNA" /><link rel="alternate" media="only screen and (max-width: 640px)" href="http://m.seekingalpha.com/article/1838602" /><meta name="original-source" content="http://seekingalpha.com/article/1838602-sarepta-therapeutics-no-longer-a-momentum-play-but-long-term-value-remains"><meta property="og:image" content="http://static.cdn-seekingalpha.com/uploads/2013/8/19/social_sa_logo.png" />
<meta property="og:title" content="Sarepta Therapeutics: No Longer A Momentum Play, But Long-Term Value Remains" />
<meta property="og:description" content="Sarepta Therapeutics (SRPT) demonstrated the binary nature of biotechnology investing Wednesday. The shorts were vindicated as the FDA told the company that it should not apply for approval based in Phase II data for eteplirs" />
<link rel="canonical" href="http://seekingalpha.com/article/1838602-sarepta-therapeutics-no-longer-a-momentum-play-but-long-term-value-remains" />
<link href="http://static1.cdn-seekingalpha.com/stylesheets/performance_layout_packaged.css?1384954027" media="screen" rel="stylesheet" type="text/css" /><link href="http://static1.cdn-seekingalpha.com/stylesheets/performance_layout_b_packaged.css?1384954027" media="screen" rel="stylesheet" type="text/css" /><link href="http://static1.cdn-seekingalpha.com/stylesheets/article_packaged.css?1384954028" media="screen" rel="stylesheet" type="text/css" />
<script type="text/javascript">var block_script = true;var jhi = 0;</script>
<script type="text/javascript" src="/javascripts/getads.js"></script>


<script type="text/javascript">
  var users_on_site='2,667,596';
  var user_cookie={};

  function readCookie(name) {
    var cookie = document.cookie.match(new RegExp('(^|;)\\s*' + escape(name) + '=([^;\\s]*)'));
    return (cookie ? unescape(cookie[2]) : null);
  }

  function addToCookie(key,value) {
    var arr=user_cookie[key].split(',');
    arr.push(value);

    user_cookie[key]=arr.join(',');
  }
  if (document.location.protocol == "https:") {
    document.write('<scr'+'ipt src="/account/no_cookie_key"></scri'+'pt>');
  } else if (readCookie('user_cookie_key')) {
    document.write('<scr'+'ipt src="http://static.cdn-seekingalpha.com/account/cookie/'+readCookie('user_cookie_key')+'"></scri'+'pt>');
  } else if (readCookie('user_id')) {
    document.write('<scr'+'ipt src="http://seekingalpha.com/account/no_cookie_key"></scri'+'pt>');
  }
  
    (function(){
      var url='/article/1838602-sarepta-therapeutics-no-longer-a-momentum-play-but-long-term-value-remains';
      if (location.pathname!=url){
        if (window.history && history.replaceState) history.replaceState("", "", url+location.search);
        else location.href=url+location.search;
      }
    })();

  var isThisMyFirstPV = false;
  var _comscore = _comscore || [];
  _comscore.push({ c1: "2", c2: "8500672" });
  (function() {
    var s = document.createElement("script"), el = document.getElementsByTagName("script")[0]; s.async = true;
    s.src = (document.location.protocol == "https:" ? "https://sb" : "http://b") + ".scorecardresearch.com/beacon.js";
    el.parentNode.insertBefore(s, el);
  })();
  var _sf_startpt=(new Date()).getTime(); // chartbeat code
  var is_pro = false;
  if (document.location.protocol == "https:") {
    document.write('<link rel="shortcut icon" type="image/ico" href="https://seekingalpha-a.akamaihd.net/favicon.ico" />')
  } else {
    document.write('<link rel="shortcut icon" type="image/ico" href="http://static.cdn-seekingalpha.com/favicon.ico" />')
  }
  
    
  var ASSET_HOSTS = ["http://static.cdn-seekingalpha.com","http://static1.cdn-seekingalpha.com","http://static2.cdn-seekingalpha.com","http://static3.cdn-seekingalpha.com"];
</script>

<script type='text/javascript'>
  if (document.location.protocol !== "https:") {
    var crtg_nid="2227";
    var crtg_cookiename="cto_sa";
    var crtg_varname="crtg_content";
    function crtg_getCookie(c_name){ var i,x,y,ARRCookies=document.cookie.split(";");for(i=0;i<ARRCookies.length;i++){x=ARRCookies[i].substr(0,ARRCookies[i].indexOf("="));y=ARRCookies[i].substr(ARRCookies[i].indexOf("=")+1);x=x.replace(/^\s+|\s+$/g,"");if(x==c_name){return unescape(y);}}return'';}
    var crtg_content = crtg_getCookie(crtg_cookiename);var crtg_rnd=Math.floor(Math.random()*99999999999);
    var crtg_url=location.protocol+'//rtax.criteo.com/delivery/rta/rta.js?netId='+escape(crtg_nid);crtg_url+='&cookieName='+escape(crtg_cookiename);crtg_url+='&rnd='+crtg_rnd;crtg_url+='&varName=' + escape(crtg_varname);
    var crtg_script=document.createElement('script');crtg_script.type='text/javascript';crtg_script.src=crtg_url;crtg_script.async=true;
    if(document.getElementsByTagName("head").length>0)document.getElementsByTagName("head")[0].appendChild(crtg_script);else if(document.getElementsByTagName("body").length>0 && !SA.Utils.Env.isIE7)document.getElementsByTagName("body")[0].appendChild(crtg_script);
  }
</script>
<script src="http://static2.cdn-seekingalpha.com/javascripts/common_packaged.js?1384953986" type="text/javascript"></script>
<script src="http://static2.cdn-seekingalpha.com/javascripts/common2_packaged.js?1384953988" type="text/javascript"></script><script src="http://static.cdn-seekingalpha.com/javascripts/common_article_packaged.js?1384953990" type="text/javascript"></script><script src="//partner.googleadservices.com/gampad/google_service.js" type="text/javascript"></script>
<script>
  if (SA.Data && SA.Data.Cache) {
    var adata = SA.Data.Cache.get('campaign_content');
  }
</script>

<script type="text/javascript">
  if ((user_email_cookie=readCookie('user_email')) && user_email_cookie.indexOf('@gmail.com')!=-1) {
    createCookie('user_email',(user_email_cookie.replace('@gmail.com','').replace(/\./gi,'').replace(/\+(.*?)$/,''))+'@gmail.com',365);
  }

  if (typeof(readCookie) == "function" && readCookie('user_vocation')) {
    createCookie('u_voc',readCookie('user_vocation'),3000);
  }
  if (readCookie('sapu') == "121") {eraseCookie('sapu');}
  var user_cookie = user_cookie || {};
  eraseCookie("__article_last_size");

if (top.location.pathname == "/" && readCookie('user_id')==957061) {
  var old_SADataCookies = SA.Data.Cookies.get;
  SA.Data.Cookies.get = function(x){if (x=="user_following_users" || x=="user_watchlist_authors") return ""; else return old_SADataCookies(x);}
}
  try{(function(){
    var uc=SA.Data.Cookies.get("user_cookie_key"), t=uc ? uc.match(/t=([0-9]+)/) : null;
    if (t && t[1] < 1367771521) SA.Data.Cookies.set("user_cookie_key","");
  })();} catch(e){}
</script>

<script type="text/javascript">var NREUMQ=NREUMQ||[];NREUMQ.push(["mark","firstbyte",new Date().getTime()]);</script>      <script type="text/javascript">
  var adblock = false;
  try{
    GS_googleAddAdSenseService("ca-pub-1420150919334552");
    GS_googleEnableAllServices();
  } catch(e) {
    adblock = true;
    Mone.event("Exception","adsense1","adsense down");
  }
</script>
<script type="text/javascript">
  try{
      GA_googleAddSlot_sa('Article_120x30');
    GA_googleFetchAds();
  } catch(e) {
    adblock = true;
    Mone.event("Exception","adsense2","adsense down");
  }
</script>  </head>
    <body class="stretch_bg">
    <script>
  var ms_slug = '';
  var article_dashboards = '@investing-ideas@sectors@';
  var article_sectors_themes = '@long-ideas@us@biotechnology@healthcare@article@';
  var ratings_hash={};
  var ARTICLE_ID = 1838602;
  var ARTICLE_TYPE = "standard";
  var ARTICLE_LOCK = "";
  var author_slug = "bryce-istvan";
  var pticker_for_ads = "srpt";
  var time_left;
  var lock_comments = false;
  var machine_cookie = readCookie('machine_cookie');
  var middle_version = ABTest.identity%10;
  var sector_name = "Healthcare";
  var sector_slug = "healthcare";
  try {
    window.sessionStorage.setItem("/article/"+ARTICLE_ID, '1');
  } catch (error) {}

  
</script>
<script>var mone_article_tags = "{gsk,rna,srpt};;;{healthcare};;;{long-ideas,us,biotechnology,investing-ideas,sa-exclusive};;;{bryce-istvan}"</script><script>var ord = Math.floor(Math.random()*1000000000);</script>
<span class="seeking_alpha_site_title">Seeking Alpha</span>
<script type="text/javascript">
  if (readCookie('sa_mobile') == '1') {
    var aHTML =[];
    aHTML.push('<div class="mobile_or_full_site">');
      aHTML.push('<span class="mobile_site" onclick="eraseCookie(\'sa_mobile\');top.location.reload()">Click here to view mobile site</span>');
      aHTML.push('<div class="cleaner"></div>');
    aHTML.push('</div>');
    document.write(aHTML.join(""));
  }
</script>
<div class="promotion_cnt finance stars ipad_top">
  <div close="close"></div>
    <a onclick='Mone.event("ipad_promotion_top","top_ipad_banner_large","ipad_promotion_top_click");' href="/download-ipad-app?source=top_ipad_banner_large" class="promotion_video">
    <div class="ptext">
      <div class="ptext_t">Seeking Alpha Portfolio App for iPad</div>
      <div class="ptext_h">Finance</div>
      <div id='ipad_stars' class="stars stars_5"></div>
      <div class="rate">(<span class="rate_num" id="rate_num">1</span>)</div>
    </div>

    <div class="free"></div>
    <div class="sep"></div>
    <div class="ipad_screenshots"></div>
  </a>
</div>
<script>
  var ipadData;
  SeekingAlpha.Initializer.AddAfterLoad(function(){
    if (SA.Utils.Env.isIPad && !/3/.test(SA.Data.Cookies.get("user_devices"))){
      Mone.event("ipad_promotion_top","top_ipad_banner_large","ipad_promotion_displayed");
      ipadData = new SA.Data.iPad();
      ipadData.instanceName = "ipadData";
      var responseHandler = new Object();
      responseHandler.handleResponse = function(data){
        if (!data.averageUserRating) return;
        var stars = data.averageUserRating < 4 ? "4" : (data.averageUserRating+"").replace(".","");
        $("ipad_stars").className = "stars stars_"+stars;
        $("rate_num").innerHTML = data.userRatingCount;
      }
      ipadData.responseDelegate = responseHandler;
      ipadData.getData();
    }
    if (SA.Utils.Env.isIPad && !/3/.test(SA.Data.Cookies.get("user_devices"))) {
      $$("body")[0].addClassName('ipad_promotion')
    }
  });
</script>
<div id="header" class="not_logged_in header_nav">
  <div id="logo_and_navigation" class="logo_and_primary_navigation">
    <div id="comment_popup" style="position:relative; left:0; display:none">
  <div id="popup_secondary">
    <div id="inner_popup"></div>
  </div>
</div>    <span class="logo_old_h1"><a href="http://seekingalpha.com/" title="Seeking Alpha - Home Page" sasource="salogo"></a></span>
    
      <div class="item banner728x90" id='top_banner_728x90'>
          <script type="text/javascript">
            iframeAd("728x90",'http://ad.doubleclick.net/adj/sek.investing-ideas/long-ideas;sz=728x90;x=x;tile=1;d=investing-ideas;t=long-ideas;aid=1838602;d=investing-ideas;d=sectors;t=long-ideas;t=us;t=biotechnology;t=healthcare;t=article;z=3;a=bryce-istvan;cnt=7;cnt=20;pr=srpt;s=gsk;s=rna;s=srpt;'+dart_my_vocation_and_profiles()+'ord='+ord+'?');
          </script>
      </div>
    
  </div>
  <div class='nav_container_wrap' id='nav_container_wrap'>
  <div id="nav_container" headtab="">
    <div id="navi_cont">
      <ul id="navi" class="navi">
        <li thistab='home' class="home">
          <a href="http://seekingalpha.com/" sasource="headtabs">Home</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='portfolio' class="portfolios">
          <a href="http://seekingalpha.com/account/portfolio" sasource="headtabs">Portfolio</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='market_news'>
          <a href="http://seekingalpha.com/currents/all" sasource="headtabs">Market Currents</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='investing_ideas'>
          <a href="http://seekingalpha.com/dashboard/investing_ideas" sasource="headtabs">Investing Ideas</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='investing_income'>
          <a href="http://seekingalpha.com/dashboard/investing_income" sasource="headtabs">Dividends &amp; Income</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='etfs'>
          <a href="http://seekingalpha.com/dashboard/etfs" sasource="headtabs">ETFs</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='macro_view'>
          <a href="http://seekingalpha.com/dashboard/macro_view" sasource="headtabs">Macro View</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='alerts'>
          <a href="http://seekingalpha.com/real-time-alerts" sasource="headtabs">ALERTS</a>
            <span class="navi_right_corner">|</span>
          </li>
          <li thistab='pro' class="pro_tab">
            <a href="http://seekingalpha.com/account/pro" sasource="headtabs">PRO</a>
          </li>
        <li class="right_section">
          <div id="user_settings_wrapper"></div>
        </li>
      </ul>
    </div>
  </div>
    <div class="rta_nav">
      <span class="rta_nav_wrap">
        <div id="rta_nav_close" onclick="SA.Promotion.Sticky.hide()" class="close_rta">&nbsp;</div>
        <div id="related_promo_container_rel_nav" class="rta_bottom" style="display:none">
  <span class="title_wrap">
    <div class="rta_bottom_title" id="related_promo_title_nav">This article was sent to <span id="promo_num_of_rta_rel_nav">5,185</span> people who get email alerts on <span class="replace_by_rel_slug">&nbsp;</span>.</div>
      <div class="title_sec">Which cover: new articles | breaking news | earnings results | dividend announcements</div>
  </span>
  <div class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('rel_nav')">Get email alerts on <span class="replace_by_rel_slug">&nbsp;</span><span class='rta_bottom_arrow'> &raquo;</span></div>
  <div class="m_pop point_left" id="promotion_box_rel_nav" style="display:none;"></div>
</div>
<div id="related_promo_container_no_rel_nav" class="rta_bottom newsletter" style="display:none">
  <div class="rta_bottom_title">
    This article was sent to <span id="dash_newsl_subscr_count_ph_nav">371,570</span> people who get the Investing Ideas newsletter.
    <span class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('no_rel_nav', 10727)">Get the Investing Ideas newsletter &raquo;</span>
    <span id="promo_no_rel_loader_nav" style="display:none;"><img height="16" width="16" src="http://static3.cdn-seekingalpha.com/images/loader.gif" /></span>
  </div>
  <div class="m_pop" id="promotion_box_no_rel_nav" style="display:none;"></div>
</div>
                              </span>
    </div>
</div>
  <script type="text/javascript">
    SeekingAlpha.Initializer.LogAndRun(SA.Navigation.Top.init);
  </script>
</div>
<div id="main_container" class="white_as_before ">
  <div id="content_wrapper" class="article_pages" itemscope itemtype="http://schema.org/Article">
    <img src="http://static.cdn-seekingalpha.com/images/universal/print_logo.png" width="48" height="20" id="print_seekingalpha_logo" />
    <div class="page_top">
      <div class="search_box_container_isolated">
  <div class="search_box">
    <form id="search_box_sa_search" method="get" class="linktosym comp search" action="/search/" onsubmit="return false;">
      <fieldset>
        <input id="autocomplete_sa_search" class="input_text text" type="text" value="search by symbol, author, keyword..." size="25" autocomplete="off" onblur="if($$('.search_box'))$$('.search_box')[0].style.background='';this.style.color=this.value=='' ? '#8D8D8D' : '#000000';handleInput(this,'blur')" onfocus="if($$('.search_box'))$$('.search_box')[0].style.background='#fff';this.style.color='#000000';handleInput(this,'focus')" afteruploadvalue='eFind quotes, people, expressions, transcripts' title='search by symbol, author, keyword...' class="find_transcripts" />
        <input type="button" class="search_button" value="" onclick="if ($('autocomplete_sa_search').value!=$('autocomplete_sa_search').title) AutoCompleteSAConfig.Packages.search.Find()" />
      </fieldset>
      <input type="hidden" name="source" value="search_general" />
      <input type="hidden" id="autocomplete_sa_hidden_search" name="q" value="" />
      <input type="hidden" name="cx" value="018269914407235029540:cdhc2yeo2ko" />
      <input type="hidden" name="cof" value="FORID:11;NB:1" />
      <input type="hidden" name="goto_search_tab" value="" />
    </form>
    <script type="text/javascript">SeekingAlpha.Initializer.LogAndRun(function () { AutoCompleteSAConfig.Load('search', { Symbols:true, IframeCover:true, AfterInsert:function () { this.Find(); }, AfterSubmit:function () { this.Find(); }}) });</script>
    <script type="text/javascript" src="http://www.google.com/coop/cse/brand?form=searchbox_018269914407235029540%3Acdhc2yeo2ko&lang=en"></script>
  </div>
</div>
      <div id="article_header" class="article_content">
  <div class="top_content">
    <div id="page_header" class="page_header_email_alerts">
      <h1>
        <span itemprop="name">Sarepta Therapeutics: No Longer A Momentum Play, But Long-Term Value Remains</span>
              </h1>
      <div id="article_info">
        
        <div class="article_info_pos">
          <span>Nov 14 2013, 03:30</span>
          <span id='title_article_comments'></span>
          <span id="page_position"></span>
          <span class="author_name_for_print">by: Bryce Istvan </span>
<span  class='print_hide'>&nbsp;|&nbsp;</span>
            <span class='print_hide'>about:</span> <span  class='print_hide' id='about_primary_stocks'><a href="/symbol/srpt" title='Sarepta Therapeutics, Inc.' sasource='article_primary_about'>SRPT</a></span>,             <span class='print_hide'>includes: </span><span id='about_stocks'><a href="/symbol/gsk" title='GlaxoSmithKline' sasource='article_about'>GSK</a>, <a href="/symbol/rna" title='Prosensa Holding N.V.' sasource='article_about'>RNA</a></span>       	</div>
        <div id="bookmark_top" class="bookmark_container">
  <div id="bookmark_title_top" class="bookmark_title">BOOKMARK<span class="added">ED</span><span class="add"> / READ LATER</span></div></span>
  <div class="bookmark_popup" id="bookmark_popup_top">
    <h2>Bookmarked</h2>
    <p>Added to your bookmarks on the Seeking Alpha homepage</p>
    <div id="btn_top" class="btn">Remove Bookmark</div>
    <div class="arr"></div>
    <div class="right_cor"></div>
  </div>
</div>
<script>
 new SA.Pages.Article.bookmark("_top");
</script>
      </div>
    </div>
  </div>
</div>
<div class="cleaner"></div>
    </div>
    <div class="cleaner"></div>
    <div id="main_content" class="no_big_gaps_main_content">
      
      <div id="article_body_container" class="no_big_gaps_article_body_container" style="float:right;">
        <div id="article_body" itemprop="articleBody">
          <div id="article_body_top2" class="disclosure_top" style="display:none;"></div>
          <p>Sarepta Therapeutics (<a href='http://seekingalpha.com/symbol/srpt' title='Sarepta Therapeutics, Inc.'>SRPT</a>) demonstrated the binary nature of biotechnology investing <span>Wednesday. The shorts were vindicated as the FDA told the company that it should not apply for approval based in Phase II data for eteplirsen, the company's drug for the treatment of Duchene's Muscular Dystrophy. However, unlike most companies that fail binary events where there is little value left, Sarepta shares still have the opportunity to recover.</p><p>An orphan disease, DMD affects roughly 30,000 boys worldwide. Sarepta's eteplirsen drug works on a specific genetic exon (exon 51) which is the cause of approximately 12.5% of total cases. Therefore, the treatable market is roughly 3,700 patients worldwide, including 1,800 in the U.S. The drug is currently in the latter stages of a Phase 2 trial, and has shown life changing efficacy for patients currently in the trial. DMD is a chronic and deadly genetic disease that affects males with the genetic defect from birth and kills most patients by age 25. Sarepta is likely to charge $300,000-$500,000 per patient annually, resulting in a total U.S. market size of between $540 and $900 million. Adding the European market could double that, leading to peak sales of well over $1 billion.</p><p><strong>Eteplirsen vs. Drisapersen</strong></p><p>Competing against Sarepta in this ultra-orphan market is Prosensa (<a href='http://seekingalpha.com/symbol/rna' title='Prosensa Holding N.V.'>RNA</a>) and its partner GlaxoSmithKline (<a href='http://seekingalpha.com/symbol/gsk' title='GlaxoSmithKline'>GSK</a>). Prosensa is developing a competing exon 51 skipping drug called drisapersen. In September, the two companies announced that drisapersen did not meet the primary endpoint of improvement on the 6 minute walk test. The company has not decided what the ultimate fate of the Prosensa program will be, but for now drisapersen is not being given to any patients.</p><p><em>(click to enlarge)</em></p><p><a href="http://static.cdn-seekingalpha.com/uploads/2013/11/1003340_13843135423598_rId7.png" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2013/11/1003340_13843135423598_rId7_thumb.jpg" /></a></p><p>This failure likely pushed the FDA to request Phase III data from Sarepta. Because the drugs work on similar mechanisms and Sarepta's data is on just 12 patients, it is easy for the FDA to ask for more. However, the Prosensa failure also provides Sarepta with an opportunity. Prosensa controls IP in Europe that would likely prevent Sarepta from operating there without a license agreement. With the drug's failure such an agreement may be in the cards, allowing the company to double its potential market.</p><p>Some have argued that drisapersen's failure demonstrates that Sarepta's drug is unlikely to work. While I disagree with that conclusion, I have no desire to rehash the arguments. For the bear case, look at EnhindrisPECorp's article &quot;<a href="http://seekingalpha.com/article/1786112-short-sarepta-dmd-drug-prognosis-is-dismal">Short Sarepta: DMD Drug Prognosis Is Dismal</a>&quot; and Adam Feuerstein's &quot;<a href="http://www.thestreet.com/story/12089371/1/a-rousing-rebuttal-of-the-sarepta-serial-short.html" rel="nofollow">A Rousing Rebuttal of the Sarepta Serial Short</a>.&quot; Additionally, look at Sarepta's original published <a href="http://onlinelibrary.wiley.com/doi/10.1002/ana.23982/full" rel="nofollow">study</a> and subsequent data releases.</p><p><strong>Increased Uncertainty</strong></p><p>The FDA's skepticism raises significant additional clinical trial and regulatory risk. First, Sarepta must design a study with endpoints that the FDA finds acceptable. Based on what Sarepta stated in its conference call <span>Wednesday, the FDA raised questions about both dystrophin production and the 6 minute walk test as appropriate endpoints. The regulatory agency will likely be heavily involved in the Phase III trial design and it remains to be seen what the trial will look like. If Sarepta is required to develop novel end points, the ultimate likelihood of trial success may be lower.</p><p>Additionally, the FDA may require a full placebo control arm for the Phase III trial. This is a significant concern, and could make trial enrollment a major challenge. Because of the invasive nature of dystrophin level testing, many parents may not be willing to enroll their boys without a guarantee that they will be on the drug. Additionally, it would double the number of patients required for a study. This potential requirement does raise some significant ethical issues and, if the FDA caves on this point, it would be a significant positive.</p><p><strong>Long Term Value</strong></p><p>Making the assumption that the drug works and the company will ultimately get approval, Sarepta's current price provides an opportunity for significant returns over the next few years. Assuming that the company continues to operate at a cash burn rate of $80-$120 million per year, which is in line with the <a href="http://seekingalpha.com/article/1833292-sarepta-therapeutics-ceo-discusses-q3-2013-results-earnings-call-transcript?part=single">company's 2013 guidance</a> of a loss of $80- $90 million per quarter, and the drug is launched in 2016 with peak revenue of $720 million, my model shows that the company is worth about $43 per share.</p><p><em>(click to enlarge)</em><a href="http://static.cdn-seekingalpha.com/uploads/2013/11/1003340_13843135423598_rId12.png" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2013/11/1003340_13843135423598_rId12_thumb.jpg" /></a></p><p>This is in line with a <a href="http://www.streetinsider.com/Analyst+Comments/Sarepta+%28SRPT%29+Eteplirsen+Delay+Impacts+DCF+by+$10sh+Each+Year+-+Deutsche+Bank/8873276.html" rel="nofollow">note released</a> Wednesday by Deutsche Bank analyst Robyn Karnauskas showing that in her model the company is worth between $47 and $55 per share using a peak sales number between $700M and $800M and a 2016 launch.</p><p>The shift in timing does mean that the company will need significantly more cash to get to profitability. Extrapolating from the company's historical cash burn, the company will probably need over $200 million to get through 2016. In many biotechs this additional cash burn would lead to heavy dilution at low prices. However, over the last quarter Sarepta took advantage of its high prices to raise $125 million in an ATM offering, leaving the company with $281 million in cash and equivalents. This large cash position should give the company enough cushion to get through 2016 without any additional equity offerings.</p><p><strong>Catalysts</strong></p><p>While the timing for Sarepta approval has likely shifted until sometime in 2016, there are several potential catalysts that could move the stock. Over the next 9 months, Sarepta will be having numerous discussions with the FDA. Depending on how transparent the company is with the outcomes of those negotiations, each press release will be heavily examined for subtle clues about the FDA's thinking. At the end of those discussions, likely mid-2014, Sarepta should have a clinical trial protocol for their Phase III trial. If the FDA agrees to allow Sarepta to use known endpoints and/or a non-placebo controlled study, it will reduce some uncertainty. Once the trial begins, enrollment pace will be closely watched. The faster the company can enroll the trial, the faster they can get to results.</p><p>In addition to the exon 51 drug, Sarepta is looking to start clinical trials for its DMD drugs targeting other exons. This is likely on hold until the company and the FDA agree on appropriate endpoints, but the company still expects to file two additional INDs by the end of 2014.</p><p>One other potential catalyst from the DMD program would be an agreement with Prosensa that opens up the European market for Sarepta. This would likely be seen as a major boost to the drug's ultimate prospects because it would essentially double the number of potential patients.</p><p>Sarepta significantly re-priced <span>Wednesday to take into account a dramatic increase in uncertainties. However, investors who are willing to accept those uncertainties and are willing to hold the stock over the next two years as the uncertainties are clarified, have a great entry point.</p>
            <div id="article_source">Source: <a href="/article/1838602-sarepta-therapeutics-no-longer-a-momentum-play-but-long-term-value-remains?source=cc">Sarepta Therapeutics: No Longer A Momentum Play, But Long-Term Value Remains</a></div>
            <!--googleoff: index-->
            <div id="article_body_top" class="disclosure_top" style="display:none;">
              <p><strong>Disclosure: </strong>I am long <a href='http://seekingalpha.com/symbol/srpt' title='Sarepta Therapeutics, Inc.'>SRPT</a>. <span id="additional_business_disclosure" style="display:none">I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.</span> <span onclick='uncollapse()' id='more_button' style='cursor:pointer'><strong>(More...)</strong></span></p>
              <span id="business_disclosure" style="display:none"></span>
            </div>
            <div style="clear:both"></div>
            <!--googleon: index-->
          
        </div>
        <script>SA.Pages.Article.handleDisclosures();</script>
        <div id="content_follow_up" class="underbar">
          <div id="follow_wrap">
              <div id="article_rta_bottom_container">
                <div id="related_promo_container_rel" class="rta_bottom" style="display:none">
  <span class="title_wrap">
    <div class="rta_bottom_title" id="related_promo_title">
      This article was sent to 
      <span id="promo_num_of_rta_rel">5,185</span>
      people who get email alerts on 
      <span class="replace_by_rel_slug">&nbsp;</span>.
    </div>
  </span>
  <div class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('rel');">
    Get email alerts on <span class="replace_by_rel_slug">&nbsp;</span><span class='rta_bottom_arrow'> &raquo;</span>
  </div>
  <div class="m_pop point_left" id="promotion_box_rel" style="display:none;"></div>
</div>

<div id="related_promo_container_no_rel" class="rta_bottom newsletter" style="display:none">
  <div class="rta_bottom_title">
    This article was sent to
    <span id="dash_newsl_subscr_count_ph">
      371,570
    </span> people who get the Investing Ideas newsletter.
    <span class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('no_rel', 10727)">
      Get the Investing Ideas newsletter &raquo;
    </span>
    <span id="promo_no_rel_loader" style="display:none;"><img height="16" width="16" src="http://static3.cdn-seekingalpha.com/images/loader.gif" /></span>
  </div>
  <div class="m_pop" id="promotion_box_no_rel" style="display:none;"></div>
</div>
<div class="fl mb10" id="roadblock_comment_unit" style="display:none">
  <div class="comments_top_area">
    <div class="comments_top_area_half">
      <div class="comments_top_area_add"><strong>Comments</strong>
      	<span id="general_comment_counter">(<span id="comments_block"></span>)</span>
      </div>
    </div>
    <div style="color:#FF6F00">
      This article has&nbsp;
      <span id="comments_block2"></span>
      &nbsp;comments. To read them or add your own, <a href="javascript:void(0)" onclick="rb=new roadblock('article crb');rb.register_show=comments_reg_show;comments_reg_show()">click here</a>.
    </div>
  </div>
</div>

<div id="techpromo_container" style="display:none" class="fl mt30 mb30 w100">
  <div id="techpromo_button" onclick="SA.Pages.Article.sendTechPromoMail()"></div>
</div>

<div id="ipadpromo_container" style="display:none" class="fl mt30 mb30 w100">
  <div id='sms_promo_line1' class='sms_line1 ml90'>The #1 Portfolio App is Now on iPad!</div>
  <div id='sms_promo_line2' class='sms_line2 ml5 fwb mt10'>Get instant notifications & never miss a critical update on your stocks!</div>
  <a href="http://seekingalpha.com/download-ipad-app?source=article_ipad_app&kind=ipad" class="fl mt30"><div id="ipadpromo_button"></div></a>
  <a href="http://seekingalpha.com/download-ipad-app?source=article_ipad_app&kind=ipad" class="fl mt20"><div id="get_the_app"></div></a>
  <div id="ipadpromo_stars" class="fl mt15"></div>
</div>

<div id="store_container" style="display:none" class="fl mt30 mb30 w100">
  <div id='sms_promo_line1' class='sms_line1 ml25'>Which Seeking Alpha App is best for you?</div>
  <div class="mt15">
    <div class="ml25">
      <div class="fl"><input id="app_portfolio" type="checkbox"/></div>
      <div class="fl fwb ml10">Seeking Alpha Portfolio</div>
      <div class="cb"></div>
    </div><div class="cb"></div>
    <div class="ml25 mt15">
      <div class="fl"><input id="app_tech" type="checkbox"/></div>
      <div class="fl fwb ml10">Tech Investor</div>
      <div class="cb"></div>
    </div><div class="cb"></div>
    <div class="ml25 mt15">
      <div class="fl"><input id="app_etf" type="checkbox"/></div>
      <div class="fl fwb ml10">ETF investor</div>
      <div class="cb"></div>
    </div><div class="cb"></div>
    <div class="ml25 mt15">
      <div class="fl"><input id="app_energy" type="checkbox"/></div>
      <div class="fl fwb ml10">Energy Investor</div>
      <div class="cb"></div>
    </div><div class="cb"></div>
    <div class="light-gray mt20 ml25">Email me a link to open from my phone:</div>
    <div class="ml25 mt5">
      <input id="email_to_download" type="text" style="width: 300px" class="fl" emailautofill="on" title="Email address" empty="Email address"/>
      <div class="bs-btn fl btn-primary ml10 btn-mini fwb" style="width: 70px;" onclick="SA.Pages.Article.sendLinkDownload()">Continue</div>
      <div class="cb"></div>
      <div class="red fs11" id="email_td_error"></div>
    </div>
  </div>
</div>

<div id="web_video_container" style="display:none" class="fl mt30 mb30">
  <iframe width="480" height="315" src="//www.youtube.com/embed/LFNN6lhLtkk" frameborder="0" allowfullscreen></iframe>
  <div class="fl mt20" style="margin-left: 194px;"><a href="http://seekingalpha.com/download-app?source=vid_bottom_article">Get the app &raquo;</a></div>
</div>

<div id="ipad_video_container" style="display:none"  class="fl mt30 mb30">
  <iframe width="480" height="315" src="//www.youtube.com/embed/zEnMPGkjOnI" frameborder="0" allowfullscreen></iframe>
  <div class="fl mt20"  style="margin-left: 194px;"><a href="http://seekingalpha.com/download-app?source=vid_bottom_article">Get the app &raquo;</a></div>
</div>


              </div>
              <div id="article_rta_middle_container" style="display:none">
                <div id="related_promo_container_rel2" class="rta_bottom" style="display:none">
  <span class="title_wrap">
    <div class="rta_bottom_title" id="related_promo_title2">
      <span id="promo_num_of_rta_rel2">
         5,185
      </span>
         &nbsp;people received this article by email alert
         <span id="second_line_midelena"><br />Add your email to get alerts on <span class="replace_by_rel_slug">&nbsp;</span> too:</span>
    </div>
  </span>
  <div id="no_checkbox_midelena"><div class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('rel2')">Get email alerts on <span class="replace_by_rel_slug">&nbsp;</span><span class='rta_bottom_arrow'> &raquo;</span></div></div>
  <div class="m_pop point_left" id="promotion_box_rel2" style="display:none;"></div>
</div>
<div id="related_promo_container_no_rel2" class="rta_bottom newsletter" style="display:none">
  <div class="rta_bottom_title">
    This article was sent to <span id="dash_newsl_subscr_count_ph2">371,570</span> people who get the Investing Ideas newsletter.
    <span class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('no_rel2', 10727)">Get the Investing Ideas newsletter &raquo;</span>
    <span id="promo_no_rel_loader2" style="display:none;"><img height="16" width="16" src="http://static3.cdn-seekingalpha.com/images/loader.gif" /></span>
  </div>
  <div class="m_pop" id="promotion_box_no_rel2" style="display:none;"></div>
</div>

              </div>
     		    <div id="article_tags" style="display:none">
              <div itemprop="articleSection" class="tagged_with">
                <span class="tagged_with_label">Tagged: </span><a href='/dashboard/investing_ideas' sasource='article_navigation'>Investing Ideas</a>, <a href='/analysis/investing-ideas/long-ideas' sasource='article_navigation'>Long Ideas</a>, <a href='/analysis/sectors/healthcare' sasource='article_navigation'>Healthcare</a>, <a href='/articles?filters=biotechnology' sasource='article_navigation'>Biotechnology</a>
              </div>
	          </div>
            <div class="share_this_page_article_bottom">
              <ul id="page_toolbar" class="page_toolbar">
  <li class="share_this_page_article_toolbar">
    <div class="share_this_page_snippet">
  <div id="first_line_info" style="width:490px">
    <div class="left"><h6><span id="share_slogan" class="fs16">Share this article with a colleague</span></h6></div>
  </div>
  <div class="widgets">
    <!-- Email -->

      <span class="email_this" onclick="email_story_to_friends('Article',1838602,'http://seekingalpha.com/article/1838602-sarepta-therapeutics-no-longer-a-momentum-play-but-long-term-value-remains')">
        <div class="email_button"></div>
        <div class="email_bubble">
          <span id="widget_email_count"></span>
          <span class="cor_right"></span>
        </div>
      </span>
    <!-- twitter -->
    <span class="twitter_small">
        <a href="https://twitter.com/share" class="twitter-share-button twitter_share" data-text="Sarepta Therapeutics: No Longer A Momentum Play, But Long-Term Value Remains http://seekingalpha.com/article/1838602-sarepta-therapeutics-no-longer-a-momentum-play-but-long-term-value-remains?source=tweet $GSK $RNA $SRPT" data-related="salphatrending" data-url=" " data-counturl="http://seekingalpha.com/article/1838602-sarepta-therapeutics-no-longer-a-momentum-play-but-long-term-value-remains?source=share" data-count="horizontal">Tweet</a>
    </span>
    <!-- Linked In -->
      <span id="linkedin_1" class="linkedin_small linkedin_share"><script type="IN/Share" data-counter="right" data-onsuccess="linkedin_callback"></script></span>
    <!-- facebook -->
    <span class="facebook_small facebook_share"><div class="fb-like" data-href="http://seekingalpha.com/article/1838602-sarepta-therapeutics-no-longer-a-momentum-play-but-long-term-value-remains?source=facebook" data-send="false" data-layout="button_count" data-show-faces="false" data-font="tahoma"></div></span>
    <!-- Plusone  -->
      <span class="plusone_wrap"><span class="plusone plusone_share"><div class="g-plusone" data-size="medium" annotation="bubble" data-width="65" data-callback="plusone_callback"></div></span></span>
    <!-- print -->
      <span class="print_this" onclick="print_article('with_comments')"><Print><div class="print_button"></div></span>
  </div>
</div>

  <script>
    SeekingAlpha.Initializer.AddAfterLoad(function(){
      new Ajax.Updater({success: 'widget_email_count'}, '/form/ajax_get_email_count', {
        method: 'get',
        parameters: {
          item_name: 'Article',
          article_id: '1838602'
        }
      });
    });
  </script>
  </li>
</ul>            </div>
            <div class="bookmark_bottom_wrapper"><div id="bookmark_bottom" class="bookmark_container">
  <div id="bookmark_title_bottom" class="bookmark_title">BOOKMARK<span class="added">ED</span><span class="add"> / READ LATER</span></div></span>
  <div class="bookmark_popup" id="bookmark_popup_bottom">
    <h2>Bookmarked</h2>
    <p>Added to your bookmarks on the Seeking Alpha homepage</p>
    <div id="btn_bottom" class="btn">Remove Bookmark</div>
    <div class="arr"></div>
    <div class="right_cor"></div>
  </div>
</div>
<script>
 new SA.Pages.Article.bookmark("_bottom");
</script></div>
	          <div id="article_bottom_about" class="article_bottom_units"></div>
            <div id="more_by_auth" class="more_by_auth"></div>
            <div id="more_by_ticker" class="article_bottom_units"></div>
            <div id="temporary_place_holder" class="mt10"></div>
            <div class="cleaner"></div>
          </div>
            <div class="comments_with_more">
              <div id="comments_section">
              </div>
            </div>
          <div class="cleaner"></div>
          <span class="article_submit_an_article_big" onclick="submit_your_article();"></span>
        </div>
      </div>
      <div id="secondary_ads" class="no_big_gaps_secondary_ads" style="float:right;">
        <div id="author_avatar">
    <div class="follow_sidebar">
      <script>var author_info_popup_timeout;</script>
<div id="author_info"> 
  <div class="author_page_tools" id="author_image_header">
    <div class="author_info_wrap">
      <a href="/author/bryce-istvan" class='this_is_a_author_pic' sasource="about_lpic"><img class="this_is_a_author_pic_img" align="center" src="http://static.cdn-seekingalpha.com/images/users_profile/001/003/340/big_pic.png?1320144828" width="115" height="115" alt="Bryce Istvan picture" onmouseover="ShowAuthorInfo();" onmouseout="HideAuthorInfo();" /></a>
 <div id="goto_edit_picture" class="goto_edit_picture" style='display:none'><span onclick="return goto_update_picture();" onmouseover="ShowAuthorInfo();" onmouseout="HideAuthorInfo();"></span></div>
        <div id="article_author_info" style="display:none;" onmouseover="clearAuthorInfoPopupTimeout();" onmouseout="HideAuthorInfo();">
          <div>
            <div class="followup_contributor_info">
  <div class="followup_contributor_info_title">
    <span>About the author: </span>
    <a href="/author/bryce-istvan" sasource="about_name">Bryce Istvan</a>
  </div>

  <div class="followup_contributor_info_on_author">
    <div class="followup_contributor_info_pic_cont">
      <div class="pic_cont">
        <div class="pic_contributor">
          <div class="the_pic">
              <a href="/author/bryce-istvan" sasource="about_pic"><img align="center" width="54" height="54" src="http://static.cdn-seekingalpha.com/images/users_profile/001/003/340/big_pic.png?1320144828" alt="Bryce Istvan picture"/></a>
          </div>
        </div>
      </div>
    </div>
    <div class="followup_contributor_info_text">
      I am a student at Drexel University majoring in finance and entrepreneurship and minoring in biology. My goal is to pursue a career combining the two interests. Currently, I am co-oping at Osage University Partners, a venture capital firm with a focus on university technologies. At Osage I am... <a href='/author/bryce-istvan' sasource='about_more'>More</a>
    </div>
    <div class="cleaner"></div>
	</div>
  <div class="followup_contributor_info_bottom_cnt">
    
    <div class="left_cnt">
      <ul class="followup_contributor_info_content_categories"><li>Blog: <a rel='nofollow' target='_blank' href='http://sites.google.com/site/biotechbriefing/'>Biotech Briefing</a></li></ul>
    </div>
  </div>

  <div class="cleaner"></div>
</div>
<div class="followup_contributor_info_on_author_bottom"></div>

          </div>
        </div>
    </div>
    <a href="/author/bryce-istvan" itemprop="author" class="author_info_name" sasource="about_lname">Bryce Istvan</a>
    <div class="cleaner"></div>
    <div class="author_info_nav_border">
      <div class="author_info_nav">
        <ul class="the_author_info_nav">
          <li><a href='/author/bryce-istvan/articles'>Articles <span>(21)</span></a></li>
                        <li>
                   <a href='/author/bryce-istvan/stocktalk'>StockTalks <span>(6)</span></a>
                 </li>            <li>
                   <a href='/author/bryce-istvan/comments'>Comments <span>(69)</span></a>
                 </li>              <script>if (/stats viewer/.test(readCookie("user_perm"))) document.write("<li><a href='/account/authorboard/earnings?for_user_id=1003340'>Earnings</a></li>");</script>
          <li><a href='/author/bryce-istvan'>Profile</a></li>        </ul>
      </div>
    </div>
    <div class="cleaner"></div>
    <div class="user_followers_following">
      <div class="user_followers">
        <a href="/author/bryce-istvan/followers">
          <span id="followers" class="number followers_number_1003340 followers_number_bryce-istvan">90</span>
          <span class="text">Followers</span>
        </a>
      </div>
      <div class="user_followers">
        <a href="/author/bryce-istvan/following">
          <span id="followings" class="number">42</span>
          <span class="text">Following</span>
        </a>
      </div>
    </div>

    <div id="follow_this_user" class="follow_this_user"></div>
    <script>Follow.author_sidebar__follow_button_initiator('bryce-istvan')</script>
    <span class='author_info_send_message' onclick='Messaging.sendMessage("3k1a3k9rd", "Article Author ID Card Upper")'>Send Message</span>
    <div class="cleaner"></div>
  </div>
  <div class="follow_popup_wrapper">
      <div class="green_pop_wrapper" id="stop_follow" style="display:none"><div class="green_pop_top_arrow"></div><div class="green_pop"><span class="close_pop" onclick="$('stop_follow').style.display='none'"></span><p><span id="stop_follow_message"></span> Bryce Istvan</p><span class="stop_following" onclick="Follow.ajax_stop_follow_this_author(this, 'bryce-istvan')">Stop Following</span></div></div><div class="green_pop_wrapper" id="no_longer_follow" style="display:none"><div class="green_pop_top_arrow"></div><div class="green_pop"><span class="close_pop" onclick="$('no_longer_follow').style.display='none'"></span><p><span id="no_longer_message"></span> Bryce Istvan</p></div></div>  </div>
</div>
  <script>SeekingAlpha.Initializer.onDOMLoad(function (){Follow.setFfToElements($('followers'),$('followings'),35374)})</script>

    </div>
    <div class="cleaner"></div>
    <span>About this author:</span>
      <ul>
        <li><a target="_blank" href="http://sites.google.com/site/biotechbriefing/">Visit Biotech Briefing</a></li>
     </ul>
    </div>
          <div class="stickyad_wrapper">
            <div class="item banner160x600" id="fixed_banner160x600">
            </div>
          </div>
      </div>
    </div>
      <script>var page_ad_src = 'http://ad.doubleclick.net/adj/sek.investing-ideas/long-ideas;sz=300x251;x=x;tile=4;d=investing-ideas;pos=b;t=long-ideas;aid=1838602;d=investing-ideas;d=sectors;t=long-ideas;t=us;t=biotechnology;t=healthcare;t=article;z=3;a=bryce-istvan;cnt=7;cnt=20;pr=srpt;s=gsk;s=rna;s=srpt;'+dart_my_vocation_and_profiles()+'ord='+ord+'?';</script>
  <div id="ads_and_tools" class="article_sidebar_tools red_sidebar">
    <div class="item banner300x600">
      <script>add_js_to_ad_call('http://ad.doubleclick.net/adj/sek.investing-ideas/long-ideas;sz=300x250,300x600;x=x;tile=2;d=investing-ideas;pos=t;t=long-ideas;aid=1838602;d=investing-ideas;d=sectors;t=long-ideas;t=us;t=biotechnology;t=healthcare;t=article;z=3;a=bryce-istvan;cnt=7;cnt=20;pr=srpt;s=gsk;s=rna;s=srpt;'+dart_my_vocation_and_profiles()+'ord='+ord+'?');</script>
    </div>
      <div id="alternative_title_container" class="mini_category data_currencies_table" style="display:none">
  <div class="sidebar_title_bk">
    <span class="sidebar_title_text" id="article_alternative_title"></span>			
  </div>
  <div id="symbol_alternative_tags" class="symbol_alternative_tags"></div>
  <div id="alternatives_pirsomet" class="alternatives_pirsomet" style="float:left;width:100%;"></div>
    <script type="text/javascript">
      ssga_always_display("Article_120x30", "http://9nl.it/i3eb/");
    </script>
  <div class="cleaner"></div>
</div>

<script type="text/javascript">
  symbol = "SRPT";
  new Ajax.Request('/articles/get_ajax_alternatives_by_symbol?symbol='+symbol, {
    asynchronous:true,
    evalScripts:true,
    method:'get',
    onComplete: function(transport) {
      if (transport.status == 200 && transport.responseText != 'failed') {
        response = transport.responseText.split("@@");
        symbolZiignight = new Ziignight('', 'SAlternative',"","symbolZiignight","symbol_alternative_tags","ETF");
        symbolZiignight.WorkJSON = eval(response[1]);
        symbolZiignight.addETF = false;
        symbolZiignight.pageType = 'Article';
        symbolZiignight.selectedSymbol = symbol;
        symbolZiignight.SAlternativePrint(-1,true);
        symbolZiignight.InsertEtfAlternativeSymbol(response[0]);
        $('article_alternative_title').innerHTML = response[0].toUpperCase() + " vs. ETF alternatives";
        $("alternative_title_container").style.display = "";
      }
    }
  });
</script>


    <div id="register_login_snippet"></div>
    
    <div id="side_customize" class="side_customize"></div>
    <div id="portfolio_form_box"></div>

      <div id="article_sidebar" class="article_sidebar">
        <div id="sidebar_down"><img src="http://static.cdn-seekingalpha.com/images/loader_recommended_articles.gif" width="64" height="64" class="loader"/></div>
      </div>

    <div id="articles_on_my_portfolio"></div>
      <div class="cleaner"></div>
      <div class="stickyad_wrapper">
        <div class="item banner300x250" id="article_dart_sticky"></div>
      </div>
       
  </div>

  <script>
      SA.Utils.Ads.add({el:$('article_dart_sticky'), HadCreated:false, size:'300x250', delta:50, info:'http://ad.doubleclick.net/adj/sek.investing-ideas/long-ideas;sz=300x251;x=x;tile=4;d=investing-ideas;pos=b;t=long-ideas;aid=1838602;d=investing-ideas;d=sectors;t=long-ideas;t=us;t=biotechnology;t=healthcare;t=article;z=3;a=bryce-istvan;cnt=7;cnt=20;pr=srpt;s=gsk;s=rna;s=srpt;'+dart_my_vocation_and_profiles()+'ord='+ord+'?'});
  </script>

<script src="http://static2.cdn-seekingalpha.com/javascripts/portfolio_form_popup_box_packaged.js?1384953999" type="text/javascript"></script>  
   </div>
  <input id="short_url" type="hidden" value="http://seekingalpha.com/a/13eoa" />
</div>

<div id='footer_break'><div></div></div><div id="footer">
  <div id="footernav">
    <div class="footernav_left">
      <a href="http://seekingalpha.com" class="footernav_logo"></a>
      <div class="footernav_boards">
        <div><span class="footer_title">TOP AUTHORS:</span>&nbsp;<a class="top_authors" href="http://seekingalpha.com/leader-board/opinion-leaders">The Opinion Leaders</a></div>
        <div class='top_boards'>
          <span class="footer_title">TOP USERS:</span>
          <a href="http://seekingalpha.com/leader-board/top-stocktalkers">StockTalkers</a> <span class="fl_dash">|</span>
          <a href="http://seekingalpha.com/leader-board/top-instablogs">Instablogs</a>
        </div>    
      </div>
      <div class="cleaner"></div>
    </div>
    
     <div class="footernav_share_buttons">
       <div class="fl">
         <div class="fb-like" data-href="http://www.facebook.com/pages/Seeking-Alpha/224867310939090" data-layout="button_count" data-show-faces="false" data-font="verdana" data-width="450">Follow us</div>
       </div>
      <div class="twitter_wrap ml0 fl"><a href="https://twitter.com/SAlphaTrending" class="twitter-follow-button twitter_share" data-show-count="false">Follow us</a></div>
    </div>
    <div class="footernav_right">
      <div class="footernav_links">
        <a href="http://seekingalpha.com/page/sa-mobile-apps" sasource="footer">Mobile Apps</a>&nbsp;&nbsp;|&nbsp;
        <a class="small_rss" href="http://seekingalpha.com/page/feeds" sasource="footer">&nbsp;&nbsp;&nbsp;&nbsp;RSS Feeds</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/about_us" sasource="footer">About Us</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/contact" sasource="footer">Contact Us</a>
      </div>
      <div class="footernav_more_links">
        <a href="http://seekingalpha.com/page/terms-of-use" sasource="footer">Terms of Use</a> |
        <a href="http://seekingalpha.com/page/privacy" sasource="footer">Privacy</a> |
        <a href="http://www.xignite.com" rel="nofollow" target="_blank">Xignite quote data</a> |
        <span>&#169; 2013 Seeking Alpha</span>
      </div>
      <div class="cleaner"></div>
      
    </div>
   
  </div>
  <div class="cleaner"></div>
</div>  <script type="text/javascript">
    Event.observe(window, 'scroll', check_positions);

    NEW_AD_DELTA = typeof(CHANGE_AD_DELTA) != "undefined" ? CHANGE_AD_DELTA : 0;
    SA.Utils.Ads.add({el:$('fixed_banner160x600'), HadCreated:false, size:'160x600', delta:NEW_AD_DELTA, info:'http://ad.doubleclick.net/adj/sek.investing-ideas/long-ideas;sz=160x600;x=x;tile=3;d=investing-ideas;t=long-ideas;aid=1838602;d=investing-ideas;d=sectors;t=long-ideas;t=us;t=biotechnology;t=healthcare;t=article;z=3;a=bryce-istvan;cnt=7;cnt=20;pr=srpt;s=gsk;s=rna;s=srpt;'+dart_my_vocation_and_profiles()+'ord='+ord+'?'});
  </script>
<script>
  document.observe('dom:loaded', function(){
    if ($('article_source')) {$('article_source').hide();}
    if (!is_pro) {$$('.arich_promobox').each(function(o){o.show()})}
    SA.Pages.Article.primary = "srpt";
    SA.Pages.Article.init();
    if (typeof(propromotion) != "undefined") {propromotion();}

    if (SA.Pages.Article.alpha_rich_article() || SA.Pages.Article.insiders_report_article()){
      update_pro_tracker(0,1,0,0);
    }
      
    if (location.href.match(/source=[a-z0-9_]*email[a-z0-9_]*/)) {createCookie('camefromrta',true);}
    var pagination_version = ABTest.identity%10;

    if (SA.Pages.Article.is_roadblock()){
      rb = new roadblock('article');
      rb.register_show = SA.Pages.Article.roadshow;
      Mone.event(rb.type,rb.source,"Half Article");
      SA.Pages.Article.cut_new(pagination_version);
    } else {
      if (!SA.Data.User.loggedIn() && (location.search.match(/[?&]source=(yahoo|nasdaq)/)) && !document.cookie.match(/\b(user_id|user_email|camefromrta)=/)) {
        SA.Pages.Article.hide_features_for_roadblock();
      }
    }
    if (/no_ads/i.test(window.location.href)) {SA.Pages.Article.strip_for_iframe()}

      SA.Pages.Article.btb();

  });
    SeekingAlpha.Initializer.AddAfterLoad(function(){ 
      SA.Pages.Article.articlePromo({"allSlugs":["gsk","rna","srpt"],"primarySlug":"srpt","dashboard_id":10727,"dashboard_title":"Investing Ideas"});
    });
</script>
      <script src="http://static2.cdn-seekingalpha.com/javascripts/jspell_packaged.js?1384954001" type="text/javascript"></script>
<link href="http://static2.cdn-seekingalpha.com/stylesheets/footer_packaged.css?1384954028" media="screen" rel="stylesheet" type="text/css" /><script type="text/javascript">
  if(typeof (authors) == "undefined" || typeof (symbols) == "undefined")
    load_remote_script("http://static.cdn-seekingalpha.com/javascripts/sa.js?1384953974");
  if(is_users_cookie_exists() && !cookieExists('tops') && typeof(tops) == "undefined")
    load_remote_script("http://static.cdn-seekingalpha.com/javascripts/tops.js?1384953751");
  Mone.renderedParams = {};
  SeekingAlpha.Initializer.AddAfterLoad(function(){SA.Performance.Utils.loadPrintStyle('http://static1.cdn-seekingalpha.com/stylesheets/print.css')});
</script>
<noscript>
  <img src="http://b.scorecardresearch.com/p?c1=2&c2=8500672&cv=2.0&cj=1" width="0" height="0" />
</noscript>
<script src="http://static.cdn-seekingalpha.com/javascripts/footer_packaged.js?1384953999" type="text/javascript"></script><div id="symbol_data_script_container"></div>
<script type="text/javascript">
SeekingAlpha.Initializer.onDOMLoad(function(){
  if(SA.Pages && SA.Pages.Account && SA.Pages.Account.Portfolios){
    var a = SA.Pages.Account.Portfolios.alertsTab;
    SA.Pages.Account.Portfolios.alertsTab = function(b){if ($('ziignight_submit')) a(b);}
if (getURLParam("pu")=="all_holdings") $("tab_"+Portfolio.current_tab).click();  
}
});
if (/\/account\/portfolio/.test(location.href)) {document.getElementsByTagName("html")[0].style.overflow = "auto"}
</script>
<style>
.portfolio_news #content_wrapper .left_content .market_currents ul#mc_news li  .bullet{* position: static;* padding:0 6px 6px 1px;}
</style>
<script>
var pubnub_test = '$|892165|17136652|12809951|52832|234601|946066|138138|119840|158117|3|6383|531163|9393711|4726401|1107427|2120371|2632411|';
try{
var auth = "|" + SA.Data.Cookies.get('user_id') + "|";
if (pubnub_test.indexOf(auth) > 0) {
var scriptElement_n = document.createElement("script");
scriptElement_n.defer = "defer";
scriptElement_n.src = 'http://static.cdn-seekingalpha.com/javascripts/utils/notify.js?144';
document.getElementsByTagName("head")[0].appendChild(scriptElement_n);
var scriptElement = document.createElement("script");
scriptElement.defer = "defer";
scriptElement.src = 'http://static.cdn-seekingalpha.com/javascripts/chat.js?148';
document.getElementsByTagName("head")[0].appendChild(scriptElement);
var fileref=document.createElement("link")
fileref.setAttribute("rel", "stylesheet")
fileref.setAttribute("type", "text/css")
fileref.setAttribute("href", "http://static.cdn-seekingalpha.com/stylesheets/chat.css?147")
document.getElementsByTagName("head")[0].appendChild(fileref)
}
} catch(e) {
}
</script>

<script type="text/javascript">if (typeof NREUMQ !== "undefined") { if (!NREUMQ.f) { NREUMQ.f=function() {
NREUMQ.push(["load",new Date().getTime()]);
var e=document.createElement("script");
e.type="text/javascript";
e.src=(("http:"===document.location.protocol)?"http:":"https:") + "//" +
  "js-agent.newrelic.com/nr-100.js";
document.body.appendChild(e);
if(NREUMQ.a)NREUMQ.a();
};
NREUMQ.a=window.onload;window.onload=NREUMQ.f;
};
NREUMQ.push(["nrfj","beacon-5.newrelic.com","c0370b1d43","334927,334964","cldeEUAJWgldEBsASkVRUwlXFRkWUA1D",0,52,new Date().getTime(),"","","","",""]);}</script>
    <div class="cleaner"></div>
  </body>
</html>
